how are companies still selling compounded semaglutide Despite FDA ruling, GLP-1s giving Novo and Lilly headaches on the market The End of Compounded Semaglutide:

Ablation of HDAC5 in the mediobasal hypothalamus leads to impaired leptin sensitivity, increased food intake and severe obesity [187]

Also noted in Table 2 , several GLP-1 RAs have demonstrated favorable effects on secondary kidney outcomes

Worsening of diabetic retinopathy: Rapid improvement in blood glucose control has been associated with transient worsening of diabetic retinopathy in people with pre-existing retinopathy

So now you have 4mg in your body, not 3mg

[DOI] [PubMed] [Google Scholar] 59.Margulies K.B., Hernandez A.F., Redfield M.M., Givertz M.M., Oliveira G.H., Cole R., Mann D.L., Whellan D.J., Kiernan M.S., Felker G.M., et al

News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s